SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-23-034346
Filing Date
2023-06-05
Accepted
2023-06-05 16:37:26
Documents
1
Period of Report
2023-06-01

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 7530
  Complete submission text file 0001209191-23-034346.txt   10228
Mailing Address 399 BOYLSTON STREET, SUITE 1100 BOSTON MA 02116
Business Address 399 BOYLSTON STREET, SUITE 1100 BOSTON MA 02116 6174259200
BioImpact Capital LLC (Reporting) CIK: 0001687078 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-38811 | Film No.: 23993111

Mailing Address 450 KENDALL STREET CAMBRIDGE MA 02142
Business Address 450 KENDALL STREET CAMBRIDGE MA 02142 617-425-9200
UBS Oncology Impact Fund L.P. (Reporting) CIK: 0001691428 (see all company filings)

State of Incorp.: E9 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-38811 | Film No.: 23993113

Mailing Address 450 KENDALL STREET CAMBRIDGE MA 02142
Business Address 450 KENDALL STREET CAMBRIDGE MA 02142 6174259200
Oncology Impact Fund (Cayman) Management L.P. (Reporting) CIK: 0001721036 (see all company filings)

State of Incorp.: E9 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-38811 | Film No.: 23993112

Mailing Address 100 BINNEY STREET CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET CAMBRIDGE MA 02142 617-949-5200
TCR2 THERAPEUTICS INC. (Issuer) CIK: 0001750019 (see all company filings)

IRS No.: 474152751 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)